1. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists
- Author
-
Katrina Armstrong, Peter W. Groeneveld, Mirar N. Bristol, Yonina R. Murciano-Goroff, Anne Marie McCarthy, Susan M. Domchek, and U. Nkiru Motanya
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Attitude of Health Personnel ,Breast Neoplasms ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,medicine ,Humans ,Genetic Testing ,030212 general & internal medicine ,Precision Medicine ,Aged ,BRCA2 Protein ,Oncologists ,medicine.diagnostic_test ,BRCA1 Protein ,business.industry ,Middle Aged ,Precision medicine ,medicine.disease ,Frequent use ,030220 oncology & carcinogenesis ,Female ,Personalized medicine ,Oncotype DX ,business - Abstract
The diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists’ uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons order BRCA 1/2 and Oncotype DX testing for breast cancer patients. We surveyed 732 oncologists and surgeons treating breast cancer patients. Physicians were from Florida, New York, New Jersey, and Pennsylvania, and were listed in the 2010 AMA Masterfile or identified by patients. 80.6% of providers ordered BRCA 1/2 testing at least sometimes and 85.4% ordered Oncotype DX (p = 0.01). More frequent ordering of BRCA 1/2 was associated with more positive attitudes toward genetic innovation (OR 1.14, p = 0.001), a belief that testing was likely to be covered by patients’ insurance (OR 2.84, p
- Published
- 2018